Kazia Therapeutics Limited ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.76 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $9.47Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $108.2M Enterprise Value $38.8M Shares Outstanding 11.4M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Kazia Therapeutics is a highly speculative, clinical-stage oncology biotech with a transformed balance sheet following a major $50 million private placement in late 2025. With approximately $46 million in cash and no debt, the company has secured an operational runway extending into 2029. Its lead asset, paxalisib (a brain-penetrant dual PI3K/mTOR inhibitor), is showing encouraging early safety and efficacy signals in advanced triple-negative breast cancer (TNBC), prompting a tripling of its Phase 1b trial enrollment. Additionally, Kazia is expanding its pipeline with first-in-class preclinical assets (NDL2 and MSETC) and preparing for pivotal registrational discussions with the FDA for paxalisib in glioblastoma. While clinical and regulatory risks remain high, the current valuation offers an asymmetric risk-reward profile backed by a robust cash cushion. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$17.49 Mean target$27.63 High · most bullish analyst$33.97 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $15.0015% The bear case is triggered by safety or tolerability hurdles in the expanded paxalisib TNBC trial, or a failure to secure a favorable registrational pathway with the FDA for glioblastoma. Additionally, if the company fails to regain Nasdaq compliance and is delisted to the OTC market, liquidity will severely contract, depressing the valuation despite the strong cash position. Base CaseCentral scenario $22.0060% The base case projects steady clinical execution of the expanded Phase 1b TNBC trial with updates throughout 2026 and 2027. Kazia successfully maintains its Nasdaq listing via a Hearings Panel appeal or reverse split. Preclinical IND-enabling work for NDL2 and MSETC progresses on schedule, and the company initiates a pivotal registrational study in GBM by early 2027, supported by its cash runway into 2029. Bull CaseUpside scenario $32.0025% The bull case assumes rapid enrollment and positive objective response rates (ORR) in the expanded Phase 1b TNBC trial, alongside FDA alignment on a streamlined registrational pathway for paxalisib in glioblastoma. Successful IND filings for NDL2 and MSETC in late 2026/early 2027 act as strong pipeline catalysts, driving institutional accumulation and a re-rating toward historical valuation multiples. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |